This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Second Sight Medical Products (EYES) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and 183.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical Products (EYES) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Second Sight Medical Products (EYES) delivered earnings and revenue surprises of -66.67% and -33.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: VALE, Second Sight, Carbonite, Arconic and vTv
by Zacks Equity Research
Zacks.com featured highlights include: VALE, Second Sight, Carbonite, Arconic and vTv
Get Over Bargain Hunting: Tap 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
by Zacks Equity Research
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
Rising P/E an Overlooked Criterion: 5 Top Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratio.
Second Sight Medical Products Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Second Sight Medical Products has been struggling lately, but the selling pressure may be coming to an end soon
Second Sight Medical Products (EYES) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 21.43% and -9.44%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?